You are here

Home > Yosef Yarden

Yosef Yarden

Human lung cancer cells harboring the L858R mutation in the EGFR gene. Cell nuclei are in blue. The red color marks a protein that is present in the cell cytoplasm when the EGFR is active and driving the uncontrolled cell divisions
A Select Group: Study May Bring Improved Therapy to Preselected Lung Cancer Patients
08.08.2023
Cancer, Personalized Medicine, Molecular and Cell Biology, Immunology, Disease, Drugs & Diagnostics

Weizmann Institute researchers identify a biomarker that may one day enable a subgroup of lung cancer patients to benefit from relapse-free...

Shutterstock
Desperate Cancer Cells
31.08.2022
Cancer, Viruses & Microorganisms, Molecular and Cell Biology, Disease, Drugs & Diagnostics, Genetics

How tumors mutate their way out of a crisis – and become drug resistant in the process

(l-r) Dr. Ashish Noronha, Prof. Yosef Yarden, and Dr. Nishanth Belugali Nataraj
To Slow Cancer, Close the Cells’ Tunnels
22.02.2022
Cancer, Molecular and Cell Biology, Disease, Drugs & Diagnostics, Genetics

A gene for transport helps aggressive cancer cells move and spread 

Prof. Yosef Yarden
Prof. Yosef Yarden
04.04.2021

Prof. Yosef Yarden has been elected to the Academy of the American Association for Cancer Research

eradicating cancer
A New Route to Blocking Children’s Bone Cancer
02.10.2019
Cancer, Personalized Medicine, Disease, Drugs & Diagnostics

A study in mice showed that reducing a particular hormone signal keeps the cancer from growing and spreading

Soma Ghosh
Dr. Soma Ghosh: Living her Dream
16.09.2019
Disease, Drugs & Diagnostics

"We attain higher achievement, better results and the opportunity to advance our scientific careers"

Prof. Yosef Yarden
Prof. Yosef Yarden
19.11.2018

Prof. Yosef Yarden is the recipient of the International Society of Oncology and Biomarkers (ISOBM) Abbott Award for Cancer Research and Tumor...

Response to treatment in cancer cells: The abundance of the EGFR (top row) and HER2 (bottom row) receptors is reduced when the cells are exposed to triple therapy – Tagrisso, Erbitux and Herceptin (right column) and to the two antibodies, Erbitux and Herceptin (second from right column), but not when they are exposed to Tagrisso alone (second column from left) or to no therapy at all (left column)
Combined Approach Offers Hope to Lung Cancer Patients Who Become Resistant to Drugs
25.07.2018
Cancer, Disease, Drugs & Diagnostics, Diagnostic Techniques and Drugs

Three drugs together block growth from without and within

Prof. Yosef Yarden
Prof. Yosef Yarden
04.09.2006
Prof. Yosef Yarden was appointed Chairman of the Israel Cancer Association’s Research Committee

Top Stories

See All >
Shutterstock

Fish under the Influence Reveal How Psychedelics Work

Shaping the Role of Future Physician-Scientists

AI Flexes Its Muscles

Social Hierarchy: Even for Mice, It’s Complicated

Press Releases
See All >
15.04.2024
Shaping the Role of Future Physician-Scientists
Shutterstock
27.03.2024
A Hundred Million Suns: The Most Complete Portrait of a Supernova
Shutterstock
18.03.2024
Fungus vs. Fungus: Newly Identified Yeast Might Prevent Life-Threatening Fungal Infections
Most Popular Articles

The Coin Toss Paradox

Can a game with “quantum” rules beat the odds?

One Protein, Two Programs

A cell’s decision to commit suicide involves an exchange of information between two suicide mechanisms

Israeli Researchers to Participate in European Commission Flagship

The European Commission has officially announced the selection of the Human Brain Project (HBP) as one of its two Future Emerging Technologies (FET) Flagship projects.